324 related articles for article (PubMed ID: 17902187)
1. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.
Kissling W; Glue P; Medori R; Simpson S
Hum Psychopharmacol; 2007 Dec; 22(8):505-13. PubMed ID: 17902187
[TBL] [Abstract][Full Text] [Related]
2. Long-acting risperidone improves negative symptoms in stable psychotic patients.
Curtis VA; Katsafouros K; Möller HJ; Medori R; Sacchetti E
J Psychopharmacol; 2008 May; 22(3):254-61. PubMed ID: 18308804
[TBL] [Abstract][Full Text] [Related]
3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
4. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
5. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
[TBL] [Abstract][Full Text] [Related]
6. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
7. Long-acting risperidone in stable patients with schizoaffective disorder.
Mohl A; Westlye K; Opjordsmoen S; Lex A; Schreiner A; Benoit M; Bräunig P; Medori R
J Psychopharmacol; 2005 Sep; 19(5 Suppl):22-31. PubMed ID: 16144783
[TBL] [Abstract][Full Text] [Related]
8. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
10. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: efficacy, quality of life and functional outcome.
Lloyd K; Latif MA; Simpson S; Shrestha KL
Hum Psychopharmacol; 2010 Apr; 25(3):243-52. PubMed ID: 20373476
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of long-acting injectable risperidone in daily practice: an open-label, noninterventional, prospective study in schizophrenia and related disorders.
Parellada E; Kouniakis F; Siurkute A; Schreiner A; Don L
Int Clin Psychopharmacol; 2010 May; 25(3):149-54. PubMed ID: 20305567
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
Lasser R; Bossie CA; Gharabawi G; Eerdekens M; Nasrallah HA
J Affect Disord; 2004 Dec; 83(2-3):263-75. PubMed ID: 15555724
[TBL] [Abstract][Full Text] [Related]
14. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients.
Girardi P; Serafini G; Pompili M; Innamorati M; Tatarelli R; Baldessarini RJ
Pharmacopsychiatry; 2010 Mar; 43(2):66-72. PubMed ID: 20099224
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone.
Schmauss M; Sacchetti E; Kahn JP; Medori R
Int Clin Psychopharmacol; 2007 Mar; 22(2):85-92. PubMed ID: 17293708
[TBL] [Abstract][Full Text] [Related]
16. Direct transition to long-acting risperidone--analysis of long-term efficacy.
Kissling W; Heres S; Lloyd K; Sacchetti E; Bouhours P; Medori R; Llorca PM
J Psychopharmacol; 2005 Sep; 19(5 Suppl):15-21. PubMed ID: 16144782
[TBL] [Abstract][Full Text] [Related]
17. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
[TBL] [Abstract][Full Text] [Related]
18. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
19. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
20. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]